menu
    • menu
    [{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"||C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cemdisiran

    Menu

    Cemdisiran

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            India Med Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Poze-Cemdi Combo Controls Intravascular Hemolysis in PNH Patients Vs Ravulizumab

                            Details : Veopoz (pozelimab) is a complement C5 inhibitor antibody, which is being evaluated in combination with cemdisiran for the treatment of paroxysmal nocturnal hemoglobinuria.

                            Product Name : Veopoz

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 07, 2024

                            Lead Product(s) : Pozelimab,Cemdisiran,Ravulizumab

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth